Bazlitoran

DB14990Investigational

Bazlitoran is under investigation in clinical trial NCT02092909 (Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia).

Mechanism: Pharmacologically active on Toll-like receptor 7, Toll-like receptor 9, and Toll-like receptor 8
Curator reviewed
Also known as: ALL-P-AMBO-2'-DEOXY-P-THIOCYTIDYLYL-(3'->5')-P-THIOTHYMIDYLYL-(3'->5')-2'-DEOXY-P-THIOADENYLYL-(3'->5')-P-THIOTHYMIDYLYL-(3'->5')-2'-DEOXY-P-THIOCYTIDYLYL-(3'->5')-P-THIOTHYMIDYLYL-(3'->5')-2'-O-METHYL-P-THIOGUANYLYL-(3'->5')-2'-O-METHYL-P-THIOURIDYLYL-( · DNA, D(P-THIO)(C-T-A-T-C-T-RGM-RUM-M5C-C7G-T-T-C-T-C-T-RGM-RUM)
Code names: IMO-8400

Resolves to

Compound

UNII2U46M95B5MCAS1378549-07-5

Targets

Q9NYK1TLR7Q9NR96TLR9Q9NR97TLR8

What you can answer from here — as of September 12, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bazlitoran, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account